Ever since menopause was first discussed publicly, the debate over the use of hormone therapy (HT) has monopolized headlines. Recognized as the most effective option for managing hot flashes and other menopause symptoms, the use of HT has continued to decline, largely as a result of the data released from the Women's Health Initiative (WHI) in 2002. New study results published in Menopause, documents the decline, along with the factors affecting a Canadian woman's likelihood of using HT.
A large proportion of the world's estimated 9.3 million breast cancer survivors experience menopausal symptoms or clinical manifestations of estrogen deficiency. A comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.
Researchers found a relationship between the genetics of tumors with germline BRCA1/2 mutations and whether the tumor retains the normal copy of the BRCA1/2 gene, and risk for primary resistance to a common chemotherapy that works by destroying cancer cells' DNA.
Breast cancer cells with defects in the DNA damage repair-genes BRCA1 and BRCA2 have a mutational signature known in cancer genomics as 'Signature 3.' But not all breast tumor cells exhibiting Signature 3 have BRCA1 or BRCA2 mutations. Therefore, some consider Signature 3 a biomarker for 'BRCAness,' a sign of a breakdown in BRCA-related DNA repair in general and not BRCA damage in particular.
A pro-tumor environment in the cell can encourage a gene to produce an alternative form of RNA that enables cancer to spread, report researchers at the Medical University of South Carolina in Nature Cell Biology.
A nanolaser known as the spaser can serve as a super-bright, water-soluble, biocompatible probe capable of finding metastasized cancer cells in the blood stream and then killing these cells, according to a new research study.
Although early detection and targeted therapies have improved patient survival, breast cancer remains a leading cause of cancer-related death for women in the United States. This week in the JCI, researchers in Jon Serody's lab at UNC Chapel Hill's Lineberger Cancer Center observed that a certain subtype of aggressive breast cancer contained high amounts of immunosuppressive cells and determined that these cells can reduce the efficacy of immune-targeting treatment strategies.
In the Journal of Clinical Investigation, UNC Lineberger Comprehensive Cancer Center researchers report on their study that explored a perplexing question: Why were drugs designed to unleash the immune system against cancer ineffective in a type of triple negative breast cancer with a heavy presence of immune cells? Their findings could lead to a strategy to improve immunotherapy responses in the 'claudin-low' subtype of breast cancer.
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School of Public Health. The link was stronger among women who worked night shifts.